Relying on its unique hypoglycemic mechanism, it reduces the absorption of glucose in the gastrointestinal tract by inhibiting SGLT-1 and increases the excretion of glucose by the kidneys by inhibiting SGLT-2.[6] Studies have found that SOTA can not only treat T2DM but can also treat T1DM.[7] Currently, SOTA has completed phase iii clinical trials (inTandem1, inTandem2, inTandem3).[8] The purpose of this meta-analysis is to analyze the therapeutic effect and safety of SOTA on T1DM, thereby providing evidence for the treatment of T1DM by SOTA. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.